首頁 > 市場調查報告書 > 製藥

呼吸器

特發性肺纖維化市場規模、佔有率和成長分析（按藥物類型、作用機制、最終用戶和地區分類）—2026-2033年產業預測

市場調查報告書

商品編碼

1898584

特發性肺纖維化市場規模、佔有率和成長分析（按藥物類型、作用機制、最終用戶和地區分類）—2026-2033年產業預測

Idiopathic Pulmonary Fibrosis Market Size, Share, and Growth Analysis, By Drug Type (Nintedanib, Pirfenidone), By Mode of Action (Antifibrotic Agents, Tyrosine Kinase Inhibitors), By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月19日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，特發性肺纖維化 (IPF) 市場規模將達到 43 億美元，到 2025 年將達到 46 億美元，到 2033 年將達到 78.9 億美元，在預測期（2026-2033 年）內，複合年成長率為 6.98%。

特發性肺纖維化 (IPF) 發生率的不斷上升，促使人們迫切需要有效的管理策略來改善患者的生活品質。不斷成長的患者群體推動了對創新治療方法的需求，並凸顯了加強針對這種棘手疾病的醫療保健服務的必要性。關鍵的市場促進因素包括有利的報銷政策和對更優治療方案日益成長的需求。人口老化、纖維化疾病的流行以及診斷技術的進步等因素進一步推動了市場成長。製藥公司正積極投資於臨床試驗和創新治療方法，以滿足未被滿足的醫療需求，從而顯著擴展治療選擇。然而，現有治療方案的限制可能會阻礙整體市場擴張，這凸顯了開發 IPF 綜合管理解決方案的迫切性。

全球特發性肺纖維化市場按藥物類型、作用機制、最終用戶和地區進行細分。依藥物類型分類，可分為尼達尼布、Pirfenidone和其他藥物類型。依作用機轉分類，可分為抗纖維化藥物、蛋白酪氨酸激酶抑制劑及其他作用機轉。依最終用戶分類，可分為醫院/診所、藥房和其他最終用戶。依地區分類，可分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

特發性肺纖維化市場促進因素

特發性肺纖維化市場受到該疾病發病率上升的顯著影響，這主要是由於人口老化以及空氣污染和職業風險因素等各種環境因素所造成的。此外，患者和醫療保健提供者對該疾病的認知不斷提高，也導致該疾病的診斷頻率增加。因此，對創新治療和管理方案的需求日益成長，進一步推動了市場需求。盛行率的上升和對更有效治療方法的尋求共同推動了特發性肺纖維化市場的擴張。

限制特發性肺纖維化市場的因素

特發性肺纖維化（IPF）市場面臨的一大障礙是現有IPF藥物價格過高。高昂的藥費使許多患者無法堅持完成處方治療，導致病情控制不佳，最終影響患者健康。這種經濟負擔不僅影響患者個體，也給醫療系統帶來額外壓力，尤其是在中低收入社區，這些地區獲得基本治療的機會仍然有限，造成了顯著的醫療資源分配不均，進一步加劇了治療這種致殘性疾病的挑戰，並阻礙了患者的整體治療。

特發性肺纖維化（IPF）市場趨勢

受遺傳學進步和特定生物標記識別的推動，特發性肺纖維化 (IPF) 市場正呈現出向個人化醫療顯著發展的趨勢。這種向個人化治療方案的轉變使醫療專業人員能夠根據每位患者的獨特特徵制定量身定做的治療策略。這種方法不僅提高了治療效果，改善了疾病管理，也有助於提升整體治療效果。隨著對個人化醫療解決方案的需求不斷成長，IPF 市場預計將持續擴張，這反映了呼吸系統疾病和其他慢性疾病領域向精準醫療發展的更廣泛趨勢。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲（MEA）
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭格局

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市集活動
主要企業市佔率（2025 年）

主要企業簡介

United Therapeutics Corporation
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Cipla Inc.
F. Hoffmann-La Roche Ltd
FibroGen Inc.
MediciNova Inc.
Jubilant Pharma Limited（Jubilant Cadista Limited）
Merck & Co. Inc.
Horizon Therapeutics Inc.
Avalyn Pharma Inc.
AstraZeneca
Novartis AG
GlaxoSmithKline plc
Genentech, Inc.
Biogen Inc.
Pfizer Inc.
AbbVie Inc.
Bayer AG
Amgen Inc.

簡介目錄

Product Code: SQMIG35H2223

Idiopathic Pulmonary Fibrosis Market size was valued at USD 4.3 Billion in 2024 and is poised to grow from USD 4.6 Billion in 2025 to USD 7.89 Billion by 2033, growing at a CAGR of 6.98% during the forecast period (2026-2033).

The rising incidence of idiopathic pulmonary fibrosis (IPF) is intensifying the need for effective management strategies to improve patient quality of life. This growing demographic is fueling demand for innovative therapeutic approaches, highlighting the necessity for enhanced healthcare services tailored to this challenging condition. Key market drivers include favorable reimbursement policies and heightened demand for superior treatment options. Factors such as an aging population, the prevalence of fibrotic diseases, and advancements in diagnostic technologies are further propelling market growth. Pharmaceutical companies are actively investing in clinical trials and innovative therapies to address unmet medical needs, significantly broadening the treatment landscape. However, limited existing treatment options may hinder overall market expansion, underscoring the urgency for comprehensive solutions in IPF management.

Top-down and bottom-up approaches were used to estimate and validate the size of the Idiopathic Pulmonary Fibrosis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Idiopathic Pulmonary Fibrosis Market Segments Analysis

The global idiopathic pulmonary fibrosis market is segmented by Drug Type, Mode of Action, End User and Region. Based on Drug Type, the market is segmented into Nintedanib, Pirfenidone, Other Drug Types. Based on Mode of Action, the market is segmented into Antifibrotic Agents, Tyrosine Kinase Inhibitors, Other Modes of Action. Based on End User, the market is segmented into Hospitals and Clinics, Pharmacies, Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Idiopathic Pulmonary Fibrosis Market

The idiopathic pulmonary fibrosis market is significantly influenced by the rising incidence of the condition, which is largely attributed to the aging population and various environmental factors, particularly air pollution and occupational hazards. Additionally, enhanced awareness among both patients and healthcare providers has led to more frequent diagnoses of this disease. As a result, there is a growing need for innovative treatment and management solutions, which drives further demand in the market. This combination of increased prevalence and the quest for better therapeutic options plays a crucial role in the expansion of the idiopathic pulmonary fibrosis market.

Restraints in the Idiopathic Pulmonary Fibrosis Market

A significant obstacle facing the idiopathic pulmonary fibrosis market is the exorbitant pricing of existing IPF medications. Many patients are dissuaded from adhering to their prescribed treatment regimens due to these high costs, leading to inadequate disease management and worsening health outcomes. This financial strain not only impacts individual patients but also places additional pressure on healthcare systems, particularly in low- and middle-income regions. In such areas, access to essential therapies remains limited and disproportionately uneven, further exacerbating the challenges associated with treating this debilitating condition and hindering overall patient care.

Market Trends of the Idiopathic Pulmonary Fibrosis Market

The idiopathic pulmonary fibrosis (IPF) market is witnessing a significant trend towards personalized medication, driven by advancements in genetics and the identification of specific biomarkers. This shift towards individualized treatment plans allows healthcare professionals to create tailor-made therapeutic strategies that cater to the unique characteristics of each patient. By enhancing the efficacy of therapies, this approach not only improves disease management but also elevates overall treatment outcomes. As the demand for personalized healthcare solutions rises, the IPF market is set to expand, reflecting a broader movement towards precision medicine in respiratory disorders and other chronic conditions.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Technology Analysis
Pipeline Analysis
Patent Analysis

Idiopathic Pulmonary Fibrosis Market, By Drug Type

Market Overview
Nintedanib
Pirfenidone
Other Drug Types

Idiopathic Pulmonary Fibrosis Market, By Mode of Action

Market Overview
Antifibrotic Agents
Tyrosine Kinase Inhibitors
Other Modes of Action

Idiopathic Pulmonary Fibrosis Market, By End User

Market Overview
Hospitals and Clinics
Pharmacies
Other End Users

Idiopathic Pulmonary Fibrosis Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2025

Key Company Profiles

United Therapeutics Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
FibroGen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MediciNova Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Jubilant Pharma Limited (Jubilant Cadista Limited)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co. Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Horizon Therapeutics Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Avalyn Pharma Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genentech, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments